We are a world-leading consumer health company with a clear purpose to deliver better everyday health with humanity.
Learn more about why we are well positioned to play a vital role for people all around the world.
Our leading brands are built on science, innovation and human understanding and are trusted by millions of consumers globally.
Learn more about our brand categories and our strong portfolio of brands.
How we’re helping to break down the social and environmental barriers that hold people back from better everyday health.
Being a responsible business is one of Haleon's four strategic priorities. See how we performed in 2022.
All the latest news and information from Haleon.
Follow us on social media.
The future of everyday health is changing and we’re the people changing it. Nowhere else will you find an opportunity quite like this.
Where you choose to work matters, both to you, and to us.
Collapse navigation.
Shareholder information
Find details below about Haleon plc's share buybacks.
On 27 February 2025, Haleon plc announced a capital allocation of £500 million for share buybacks during 2025.
On 21 March 2025, Haleon completed an off-market buyback of c. 44m shares from Pfizer Inc for approximately £170m.
On 28 March 2025, we announced the commencement of a share buyback programme for up to £330m. This represents the remainder of the £500m allocated to share buybacks in 2025. The first tranche of the buyback programme commenced on 28 March 2025 for an aggregate consideration of c. £200m and concluded on 26 June 2025 with Haleon re-purchasing c. 51m shares.
On 31 July 2025, we announced the commencement of the second tranche of the buyback programme for an aggregate consideration of c. £280m. This was made up of c. £130m to complete the remainder of the £500m allocated to share buybacks in 2025 and a further c. £150m for the purposes of satisfying Haleon's obligations under its existing employee share plans in 2026 and 2027. The second tranche of the buyback programme concluded on 1 October 2025 with Haleon re-purchasing c. 80.6m shares.
On 29 February 2024, Haleon plc announced a capital allocation of £500 million for share buybacks during 2024.
We returned £500m to shareholders through off-market buybacks of shares from Pfizer Inc. of £315m and £115m in March and October 2024, respectively, with the remaining £70m completed through an on-market buyback programme which commenced on 1 August 2024 and ceased on 1 October 2024.
Related